Developing pharmaceutical treatments for peripheral artery disease

Expert Opinion on Investigational Drugs

Volumn 12, Issue 1, 2003, Pages 101-108

  Duprez, Daniel A ^a   De Buyzere, Marc L ^b   Hirsch, Alan T ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cardiovascular morbidity and mortality; Intermittent claudication; Peripheral artery disease; Pharmacological treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHYLLINE; ANTITHROMBOCYTIC AGENT; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFLOMEDIL; CARNITINE; CILOSTAZOL; CLOPIDOGREL; COUMARIN ANTICOAGULANT; CYANOCOBALAMIN; FIBRIC ACID DERIVATIVE; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETANSERIN; NAFTIDROFURYL; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; PENTOXIFYLLINE; PICOTAMIDE; PROPIONYLCARNITINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; PYRIDOXINE; RAMIPRIL; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; UNINDEXED DRUG; VERAPAMIL;

ARTERY DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; FLUSHING; FUTUROLOGY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HOMOCYSTINURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; HYPERTENSION; INTERMITTENT CLAUDICATION; META ANALYSIS; MORBIDITY; MORTALITY; NEUTROPENIA; REVIEW; SMOKING; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TREATMENT PLANNING; VERTIGO;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; INTERMITTENT CLAUDICATION; PLATELET AGGREGATION INHIBITORS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037234513     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.1.101     Document Type: Review

References (72)

1. BEEBE HG: Intermittent claudication: effective medical management of a common circulatory program. Am. J. Cardiol. (2001) 87(Suppl.):14D-18D.
2. COCCHERI S, PALARETTI G: The cardiovascular risk burden of intermittent claudication. Eur. Heart J. (2002) 4(Suppl. B):B46-B49.
3. HIATT W: Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity. Eur. Heart J. (2002) 4(Suppl. B):B50-B84.
4. SCHMIEDER FA, COMEROTA AJ: Intermittent claudication: magnitude of the program, patient evaluation and therapeutic strategies. Am. J. Cardiol. (2001) 87(Suppl.):3D-13D.
5. HIRSCH AT, TREAT-JACOBSON D, LANDO HA, HATSUKAMI DK: The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc. Med. (1997) 2:243-251.
6. KANNEL WB, MC GEE DL: Update on some epidemiologic features of intermittent claudication: the Framingham Study. J. Am. Geriatr. Soc. (1985) 33:13-18.
7. KANNEL WB, MC GEE DL: Diabetes and cardiovascular disease. The Framingham Study. JAMA (1979) 241:2035-2038.
8. KANNEL WB, DAGOSTINO RB, WILSON PW et al.: Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am. Heart J. (1990) 120:672-676.
9. FOWKES FG, HOUSLY E, RIEMERSMA RA et al.: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am. J. Epidemiol. (1992) 135:331-340.
10. BEACH KW, STRANDNESS DE: Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes (1980) 29:882-888.
11. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet (1998) 352:837-853.
12. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effective of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS). Lancet (1998) 352:854-865.
13. SMITH I, FRANKS PJ, GREENHALGH RM, POULTER NR, POWELL JT: The influence of smoking cessation and hypertriglyceridemia in the progression of peripheral arterial disease and the onset of critical ischemia. Eur. J. Endovasc. Surg. (1996) 11:402-408.
14. POMREHN P, DUNCAN B, WEISSFELD L et al.: The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease: the lipids research clinics program prevalence study. Circulation (1986) 73(Suppl. I):I100-I107.
15. DREXEL H, STEURER J, MUNTWYLER J et al.: Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation (1996) 94 (Suppl. II): II199-II205.
16. VALENTINE JR, GRAYBURN PA, VEGA GL, GRUDY M: Lp(a) lipoprotein is an independent, discriminating risk factor for premature atherosclerosis among white men. Arch. Intern. Med. (1994) 154:801-806.
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
18. ELAMN MB, HUNNINGHAKE DB, DAVIS KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA (2000) 284:1263-1270.
19. LENG GC, PRICE JF, JEPSON RG: Lipid-lower for lower limb atherosclerosis (Cochrane Review). Cochrane Database Syst. Rev. (2000) 2:CDO00123.
20. DUFFIELD RGM, LEWIS B, MILLER NE, JAMESON CW, BRUNT JN, COLCHESTER AC: Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis; a randomised controlled trial. Lancet (1983) 2:639-642.
21. SALONEN R, NYYSONEN K, PORKKALA E et al.: KAPS: a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation (1995) 92:1758-1764.
22. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). JAMA (2001) 285:2486-2497.
23. MURABITO JM, D'AGOSTINO RB, SILBERSHATZ H, WILSON WF: Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation (1997) 96:44-49.
24. SOLOMON SA, RAMSAY LE, YEO WW, PARNELL L, MORRIS-JONES W: β-blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. Br. Med. J. (1991) 303:1100-1104.
25. RADACK K, DECK C: Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch. Intern. Med. (1991) 151:1769-1779.
26. POLDERMANS D, BOERSMA E, BAX JJ et al.: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N. Engl. J. Med. (1999) 341:1789-1794.
27. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. (2000) 342:145-153.
28. TASC: Management of peripheral arterial disease. Transatlantic Intersociety Consensus. J. Vasc. Surg. (2000) 31:S92-S93.
29. GRAHAM IM, DALY LE, REFSUM HM et al.: Plasma homocysteine as a risk for vascular disease: the European Concerted Action Project. JAMA (1997) 227:1775-1781.
30. CLARKE R, DALY L, ROBINSON K et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. (1991) 324:1149-1155.
31. BOUSHEY CJ, BERESFORD SA, OMERIN GS, MOTULSKY AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. N. Engl. J. Med. (1991) 324:1149-1155.
32. ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ(2002) 324:71-86.
33. BALSANO F, VIOLI F, ADEP GROUP: Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation (1993) 87:1563-1569.
34. JANZON L, BERGQVIST D, BOBERG J et al.: Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicenter Study. J. Intern. Med. (1990) 227:301-308.
35. BALSANO F, COCCHERI S, LIBRETTI A et al.: Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J. Lab. Clin. Med. (1989) 114:84-91.
36. BERGQVIST D, ALMGREN B, DICKINSON JP: Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentrc Study (STIMS). Eur. J. Vasc. Endovasc. Surg. (1995) 10:69-76.
37. BENNETT CL, WEINBERG PD, ROZENBERG-BEN-DROR K, YARNOLD PR, KWAAN HC, GREEN D: Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann. Intern. Med. (1998) 128:541-544.
38. HANKEY GJ, SUDLOW CL, DUNBABIN DW. Thienopyridine derivates (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst. Rev. (2000) 2:CDO01246.
39. CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348:1329-1339.
40. BENNETT CL, CONNORS JM, CARWILE JM et al.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med. (2000) 342:1773-1777.
41. Prevention of atherosclerotic complications: controlled trial of ketanserin. BMJ (1989) 298:424430.
42. Randomized placebo-controlled, double blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure: PACK Claudication Substudy. Circulation (1989) 89:1544-1548.
43. MONEY SR, HERD JA, ISAACSOHN JL et al.: Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J. Vasc. Surg. (1998) 27:267-274.
44. DAWSON DL, CUTLER BS, MESSNER MH, STRANDNESS DEJ: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter randomised, prospective, double-blind trial. Circulation (1998) 98:678-686.
45. BEEBE HG, DAWSON DL, CUTLER BS et al.: A new pharmacological treatment for intermittent claudication: results of a randomised, multicenter trial. Arch. Intern. Med. (1999) 159:2041-2050.
46. DAWSON DL, CUTLER BS, HIATT WR et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. (2000) 109:523-530.
47. STRANDNESS DE Jr, DALMAN RL, PANIAN S et al: Effect of cilostazol in patients with intermittent claudication: a randomised, double-blind, placebo-controlled study. Vasc. Endovasc. Surg. (2002) 36:83-91.
48. HIATT WR: Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. (2001) 344:1608-1621.
49. SAMKASKA CP, WINFIELD EA: Pentoxifylline. J. Am. Acad. Dermatol (1994) 30:603-621.
50. PORTER JM, CUTLER BS, LEE BY et al.: Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. (1982) 104:66-72.
51. LINDGARDE F, JELNES R, BJORKMAN H et al.: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation (1989) 80:1549-1556.
52. GIROLAMI B, BERNARDI E, PRINS MH et al.: Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or naftidrofuryl: a meta-analysis. Arch. Intern. Med. (1999) 159:337-345.
53. HOOD SC, MOHER D, BARBER GG: Management of intermittent claudication with pentoxifylline: meta-analysis of randomised controlled trials. CMAJ (1996) 155:1053-1059.
54. ERNST E: Pentoxifylline for intermittent claudication: a critical review. Angiology (1994) 45:339-345.
55. RADACK K, WYDERSKI RJ: Conservative management of intermittent claudication. Ann. Intern. Med. (1990) 113:135-146.
56. LEHERT P, COMTE S, GAMAND S, BROWN TM: Naftidrofuryl in intermittent claudication: a retrospective analysis. J. Cardiovasc. Pharmacol. (1994) 23(Suppl. 3):S48-S52.
57. MOODY AP, AL-KHAFFAF HS, LEHERT P, HARRIS PL, CHARLESWORTH D: An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J. Cardiovasc. Pharmacol. (1994) 23(Suppl. 3):S44-S47.
58. TRUBESTEIN G, BOKME H, HEIDRICH H et al.: Naftidrofuryl in chronic arterial disease: results of a controlled multicenter study. Angiology (1994) 35:701-708.
59. ADHOUTE G, ANDREASSIAN B, BOCCALON H et al.: Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J. Cardiovasc. Pharmacol. (1990) 16(Suppl. 3):S75-S80.
60. ADHOUTE G, BACOURT F, BARRAL M et al.: Naftidrofuryl in chronic arterial disease: results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology (1986) 37:160-169.
61. KRIESSMANN A. NEIS A: Demonstration of the clinical effectiveness of naftidrofuryl in intermittent claudication. VASA (1988) 24:27-32.
62. TRUBESTEIN G, BALZER K, BISLER H: Buflomedil in arterial occlusive disease: results of a controlled multicentre study. Angiology (1984) 35:500-505.
63. DIAMANTOPOULOS EJ, GRIGORIADOU M, IFANTI G, RAPTY SA. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Int. Angiol. (2001) 20:337-344.
64. BREVETTI G, PERNA S, SABBA C, MARTONE VD, CONDORELLI M: Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J. Am. Coll. Cardiol. (1995) 26:1411-1416.
65. BREVETTI G, DIEHM C, LAMBERT D: European multicenter study on propionyl-L-carnitine in intermittent claudication. J. Am. Coll. Cardiol. (1999) 34:1618-1924.
66. BREVETTI G, PERNA S, SABBA C et al.: Superiority of L-propionylcarnitine versus L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, crossover study. Eur. Heart J. (1992) 13:251-255.
67. BALSANO F, COCCHERI S, LIBRETTI A et al.: Ticlopidine in the treatment of intermittent claudication: a 21 -month double-blind trial. J. Lab. Clin. Med. (1989) 114:84-91.
68. ARCAN JC, BLANCHARD J, BORSSEL JP, DESTORSE JM, PANNAH E: Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology (1988) 39:802-811.
69. BELCH JJF, BELL PRF, CREISSEN D et al.: Randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug in patients with intermittent claudication. Circulation (1997) 95:2298-2302.
70. LIEVRE M, AZOULY S, LION L, MORAND S, GIRRE JP, BOISSEL JP: A dose effect study of beraprost sodium in intermittent claudication. J. Cardiovasc. Pharmacol. (1996) 27:788-793.
71. LIEVRE M, MORAND S, BESSE B, FIESSINGER JN, BOISSEL JP: Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomised, multicenter controlled trial. Circulation (2000) 102:426-431.
72. HIRSCH AT, HIATT WR, CRIQUI MH et al.: PARTNERS: A National Survey of Peripheral Arterial Disease (PAD) Symptoms and Treatment Intensity J. Am. Coll. Cardiol. (2001) 37(2, Suppl. A):226A.